Tanvex BioPharma (6541.TW) Earnings Analysis

Tanvex BioPharma (6541.TW) next reports earnings on 2026-08-06, consensus EPS -1.66 TWD. Last quarter (2026-03-04) it missed with EPS -1.6 TWD vs -0.755 TWD est (-111.9%). It has beaten estimates in 0/1 recent quarters (0%). Trailing P/E -7.16.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 6541.TW next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate-1.66 TWD
Revenue estimate0.12B

6541.TW earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-04-1.6 TWD-0.755 TWD-111.9%Miss
2025-08-14-1.42813 TWDn/an/an/a
2025-03-12-1.69566 TWDn/an/an/a
2024-11-08-1.94 TWDn/an/an/a
2024-08-09-2.31087 TWDn/an/an/a

Beat rate: 0/1 (0%) over reported quarters with consensus data.

6541.TW valuation and analyst view

Trailing P/E-7.16
Trailing EPS-5.38176 TWD
Price / book1.97
Dividend yield0.00%
Market cap10.60B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Tanvex BioPharma (6541.TW)'s next earnings date?

Tanvex BioPharma is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -1.66 TWD and revenue estimate of 0.12B.

Did 6541.TW beat earnings last quarter?

In its 2026-03-04 report, 6541.TW posted EPS of -1.6 TWD versus a -0.755 TWD estimate — a miss of 111.9%.

What is 6541.TW's earnings track record?

Over the last 1 reported quarters with consensus data, 6541.TW beat estimates 0 times (0%).

What is 6541.TW's current P/E ratio and EPS?

6541.TW trades at a trailing P/E of -7.16 on trailing EPS of -5.381758225966865 TWD.

What do analysts rate 6541.TW?

6541.TW has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.